Ofatumumab Therapy for MS With Serum IgG Maintenance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing B cell-depleting therapies for multiple sclerosis (MS) lead to undesirable reductions in serum immunoglobulin levels, particularly IgG, increasing the risk of infections, which is a critical concern for long-term treatments.
Innovation Solution
Administer ofatumumab, a fully human monoclonal antibody, and monitor serum IgG levels to maintain them within the range of untreated patients, selecting ofatumumab if levels decrease or an increased infection risk is identified.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If B cell-depleting therapies are administered to treat multiple sclerosis, then disease progression is slowed, but serum IgG levels decrease and infection risk increases
Solution Approach 1:
The patent changes the key parameter from complete B cell depletion to selective B cell modulation, maintaining IgG levels above a critical threshold (e.g., 7 g/L) while still achieving disease control. This parameter change resolves the contradiction by allowing therapeutic efficacy without the harmful side effect of severe immunosuppression
Solution Approach 2:
The treatment protocol incorporates monitoring of serum IgG levels as feedback to guide therapy duration and intensity. When IgG levels approach critical thresholds, treatment is adjusted or interrupted, creating a closed-loop system that maintains disease control while preventing dangerous drops in immunoglobulin levels
2Duration of action of stationary object
If long-term B cell-depleting therapy is used, then MS symptoms are controlled, but cumulative IgG depletion increases infection susceptibility
Solution Approach 1:
The patent employs periodic treatment cycles with interruption periods, rather than continuous therapy. Treatment is administered in cycles with breaks allowed when IgG levels recover, enabling long-term disease management while periodically restoring immune function to reduce cumulative infection risk
Solution Approach 2:
The protocol establishes predetermined IgG level thresholds that trigger treatment interruption or dose reduction before dangerous immunosuppression occurs. This proactive approach cushions against the cumulative harmful effects of long-term therapy by preventing IgG levels from dropping to infection-risk zones
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ofatumumab therapy maintains serum IgG levels, reducing the risk of infections and providing a stable, long-term treatment option without the adverse effects seen with other B cell-depleting therapies.
Implementation Method 1
Ofatumumab, a fully human monoclonal antibody approved for refractory chronic lymphocytic leukemia, results in greater CDC than ADCC activity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention concerns ofatumumab for use in the treatment of multiple sclerosis (MS), wherein the treatment is a long-term treatment and wherein serum IgG level is maintained during the treatment. The invention further relates to B cell and/or T cell inhibitors for use in the treatment of MS, said treatment comprising monitoring serum IgG level and selecting ofatumumab as the B cell and/or T cell inhibitor if the serum IgG level decreases and/or said treatment comprising assessing the predisposition of the patient for an increased risk of infections and selecting ofatumumab as the B cell and/or T cell inhibitor if a predisposition is identified. The invention further relates to ofatumumab for use in the treatment of multiple sclerosis, wherein patients having a lowered serum IgG level are treated and/or wherein patients having risk factors associated with serum Ig levels, in particular serum IgG levels, are treated.